Litifilimab

• CAT Number: I040853
• CAS Number: 2407378-48-5
• Purity: ≥95%

Litifilimab (Cat No.: ) is a humanized monoclonal antibody that targets BDCA2 (blood dendritic cell antigen 2), a receptor uniquely expressed on plasmacytoid dendritic cells (pDCs). By binding BDCA2, Litifilimab inhibits type I interferon production, a key driver in autoimmune diseases like systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). It modulates immune responses by suppressing pDC activation, offering a novel therapeutic approach for interferon-driven disorders. Litifilimab is a valuable tool in autoimmune and immunology research. For research use only.

Reference

[1]. Cho SK, et al. Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus. Expert Opin Investig Drugs. 2023 May;32(5):345-353.
[Content Brief]

[2]. Litifilimab. IMGT/mAb-DB.